Microcide Pharmaceuticals, Inc.. The Company is biopharmaceutical company which discovers, develops and commercializes novel antimicrobials for the improved treatment of serious bacterial, fungal and viral infections. The company's three discovery research platforms addresses the growing problems of antibiotic resistance and the need for improved antifungal and antiviral therapeutics. The Cephalosporin Antibiotics and Efflux Pump Inhibition platforms focus on developing novel and antibiotics and antibiotic potentiators to address bacterial and fungal resistance problems. The Microbial Genomics platform utilizes proprietary bacterial, fungal and viral genetics and genomics tools to discover new classes of antimicrobial agents.